OVER 1 MILLION DOGS TREATED WITH ZENRELIA WORLDWIDE SINCE LAUNCH¶
Zenrelia™ gets 45% more itchy dogs back to normal than Apoquel®1**
Watch the video to find out more about Zenrelia
Raising expectations: aiming for normal with itchy dogs†
Back to normalZenrelia (Ilunocitinib) gets 45% more itchy dogs back to normal than Apoquel (Oclacitinib)1**
Once-daily dosingSimple, consistent once daily dosing from the start, with no treatment breaks for vaccination required2*
24 HOUR Itch Relief1,6Zenrelia targets itch where it starts2
Safety profileSafety profile comparable to Apoquel1
Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.§
For itch, don’t just manage owner expectations—set new ones
79% of owners expect their dog to be back to normal when they treat their itch.†3 But expectations don’t always match reality.1
Zenrelia gets 45% more itchy dogs back to normal vs Apoquel1**
Proportion of itchy dogs getting back to normal
A 'normal' itch score is considered to be comparable to that of a healthy, non-allergenic dog (PVAS <2).1
Want to know more? Read the full study:
Veterinary experts rate Zenrelia
"Allergies are going to remain with us for the rest of our lives, so to have an additional drug that helps those patients suffering from atopic dermatitis, or from itchiness, or from allergy is very, very exciting, because obviously it makes the dogs happier, the owners more grateful and our lives as veterinary surgeons more rewarding. Would I prescribe Zenrelia? Definitely, I can't wait to prescribe it!"
Prof Anette Loeffler DrMedVet, PhD, DVD, DipECVD, FHEA MRCVS
Professor in Veterinary Dermatology
"When they interviewed the clients with pets with skin disease, they asked what they were expecting after treatment. Only 12% of clients would have been happy with a 50% improvement in itch, and actually 79% of clients expected their pet to go back to normal”
Dr Natalie Barnard BVetMed, CertVD, DipECVD, MRCVS
RCVS and European Specialist in Veterinary Dermatology
What is Zenrelia?
Zenrelia is a NEW JAK inhibitor containing ilunocitinib for dogs with allergic and atopic dermatitis2.
It treats:
Questions?
Zenrelia Resources
¶ Elanco global sales data. December 2025
α Referenceable claims in digital & social copy can be found on this page. Full reference list below.
** 77% of dogs treated with Zenrelia achieved PVAS <2 by Day 112 compared to 53% of dogs treated with Apoquel. A 'normal' itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).1
† A 'normal' itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).1
* Please refer to SPC section 3.8 for more information.2
§Based on the average list price of Zenrelia (vs other licensed JAKi’s for dogs)
BID, twice-daily; IRTT, investigator-assessed response to treatment; ORTT, owner-assessed response to treatment; SID, once daily; VAS, visual analogue scale.
- Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176.
- Zenrelia Summary of Product Characteristics
- Rybnícek J et al. Vet Dermatol. 2009 Apr;20(2):115-22
- Gedon NKY, Mueller RS. Clin Transl Allergy. 2018 Oct; 8:41.
- Bond R et al. Vet Rec. 2007 Apr; 160:503–6.
- Unpublished data (107): Field Study for Control of Pruritus Associated with Allergic Dermatitis
- Olivry T, Mueller RS. BMC Vet Res. 2017 Feb;13(1):51.
- Mueller RS et al. BMC Vet Res. 2016 Jan; 12:9.
- Unpublished data: Owner Pruritus Assessment (PVAS) form
- Mason K et al. Vet Dermatol. 2023 May;34:115–24
